ALLMedicine™ Glucagon Center
Research & Reviews 7,230 results
https://doi.org/10.1007/s12325-022-02223-0 10.1056/NEJM199309303291401 10.1038/labinvest.3700445 10.2337/db08-0061 10.2337/db07-1726 10.1056/NEJM198302173080709 10.1038/ki.1987.174 10.1056/NEJM199311113292004 10.1056/NEJMoa011161 10.1056/NEJMoa011303 10.1056/NEJMoa1811744 10.1056/NEJMoa2024816 10.1056/NEJMoa1616011 10.1001/jama.2018.18269 10.1056/NEJMoa2025845 10.1056/NEJMoa2110956 10.2337/db11-1824 10.1155/2013/248563 10.1016/j.kint.2020.06.024 10.1111/dom.14158 10.1681/ASN.V10122569 10.1161/CIRCULATIONAHA.113.005081 10.1016/j.jdiacomp.2018.04.011 10.1007/s12325-021-01735-5 10.1038/ki.2010.526 10.1016/j.semnephrol.2012.07.010 10.1016/j.jdiacomp.2013.03.003 10.1167/iovs.12-10207 10.1002/2211-5463.12400 10.1038/srep26428 10.1167/iovs.11-8447 10.1126/science.1227166 10.1016/j.cmet.2006.01.004 10.1210/endo.137.7.8770921 10.1681/ASN.2006070778 10.1016/j.mce.2010.04.022 10.1155/2016/1379274 10.1038/s41598-020-62579-7 10.1096/fj.11-202994 10.2337/db13-1029 10.1155/2021/2182225 10.1007/s11906-017-0778-2 10.2174/1574884713666181116100946 10.1186/s12882-016-0337-0 10.1097/FJC.0000000000000366 10.1161/HYPERTENSIONAHA.117.10360 10.1097/FJC.0000000000000091 10.1016/j.ejphar.2021.174583 10.1016/j.heliyon.2022.e08878 10.1161/HYPERTENSIONAHA.116.08526 10.1681/ASN.2016040477 10.1093/eurheartj/eht187
Advances in Therapy; Mima A
Jun 26th, 2022 - Diabetic kidney disease (DKD) is one of the most important diabetic complications. DKD is also the most common cause of chronic kidney disease (CKD) and end-stage renal disease. This review focused on potential therapeutic drugs for which there is...
https://doi.org/10.1152/ajpheart.00031.2022
American Journal of Physiology. Heart and Circulatory Phy... Kiernan R, Persand D et. al.
Jun 25th, 2022 - Obesity-related cardiovascular complications are a major health problem worldwide. Overconsumption of the Western diet is a well-known culprit for the development of obesity. While short-term weight loss through switching from a Western diet to a ...
https://doi.org/10.1007/s00125-022-05732-3 10.1007/s00125-017-4342-z 10.1056/NEJMsa2032271 10.1056/NEJMoa066224 10.1056/NEJMoa1109333 10.1016/s0140-6736(17)33102-1 10.1016/s2213-8587(18)30051-2 10.1371/journal.pmed.1002654 10.1016/s2213-8587(19)30087-7 10.1007/s00125-021-05490-8 10.1038/s41588-018-0084-1 10.1007/s00125-017-4210-x 10.1056/NEJMoa032922 10.1056/NEJMoa061759 10.1016/S0140-6736(03)14571-0 10.1046/j.1464-5491.2000.00305.x 10.1001/jama.2013.283980 10.1038/ng.735 10.1038/ng.3632 10.2337/dc21-1152 10.1016/s2213-8587(14)70050-6 10.1007/s00125-015-3588-6 10.2337/db20-1281 10.2337/db15-1063 10.2337/db19-0236 10.2337/dc18-2182 10.1038/s41586-019-1231-2 10.2337/dc10-1616 10.2337/dc13-0410 10.1136/bmjopen-2019-034716 10.2337/dc18-0344 10.2337/dc17-1827
Diabetologia Florez JC, Pearson ER
Jun 25th, 2022 - Current pharmacological treatment of diabetes is largely algorithmic. Other than for cardiovascular disease or renal disease, where sodium-glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists are indicated, the choic...
https://doi.org/10.1038/s41467-022-31328-x 10.1016/j.diabres.2018.02.023 10.1016/S0140-6736(17)30058-2 10.1038/s41574-021-00489-y 10.1016/j.mce.2015.07.003 10.1016/j.bmc.2017.10.047 10.1016/S2213-8587(21)00113-3 10.1016/j.molmet.2020.101090 10.1016/j.molmet.2013.12.001 10.1016/j.peptides.2018.04.008 10.1016/S0140-6736(18)30726-8 10.1111/dom.13494 10.1111/cob.12433 10.1016/j.eclinm.2021.101088 10.1111/jcpt.13225 10.1186/s12933-016-0490-6 10.1210/jc.2018-00050 10.1002/phy2.112 10.1111/bcp.13688 10.1111/cob.12432 10.1016/j.metabol.2019.153997 10.1111/dom.12585 10.2337/db12-0797 10.1111/dom.14232
Nature Communications; Jiang H, Pang S et. al.
Jun 25th, 2022 - The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-control...
https://clinicaltrials.gov/ct2/show/NCT04883346
Jun 24th, 2022 - This is an open-label Phase II non-randomized pilot study conducted at the NIH Clinical Center to investigate the efficacy of daily subcutaneous injection of liraglutide, a glucagon-like peptide-1 (GLP1) analogue to promote reduction of body mass ...
Guidelines 4 results
https://doi.org/10.1016/j.eprac.2022.03.010
Endocrine Practice : Official Journal of the American Col... Cusi K, Isaacs S et. al.
May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...
https://doi.org/10.1016/j.kint.2020.06.024
Kidney International; de Boer IH, Caramori ML et. al.
Jul 13th, 2020 - Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeuti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782
Diabetes Care; Buse JB, Wexler DJ et. al.
Dec 21st, 2019 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245208
Diabetes Care; Davies MJ, D'Alessio DA et. al.
Oct 7th, 2018 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation ...
Drugs 79 results see all →
Clinicaltrials.gov 1,002 results
https://clinicaltrials.gov/ct2/show/NCT04883346
Jun 24th, 2022 - This is an open-label Phase II non-randomized pilot study conducted at the NIH Clinical Center to investigate the efficacy of daily subcutaneous injection of liraglutide, a glucagon-like peptide-1 (GLP1) analogue to promote reduction of body mass ...
https://clinicaltrials.gov/ct2/show/NCT02363335
Jun 24th, 2022 - Objectives and Specific Aims: We plan to investigate whether phosphodiesterases are involved in the regulation of glucagon-like peptide-1 (GLP-1) secretion from L cells in humans. We hypothesize that: (1) phosphodiesterase-4D (PDE4D) inhibitor (ro...
https://clinicaltrials.gov/ct2/show/NCT05254314
Jun 23rd, 2022 - This is a proof-of-principal randomized, double-blind, placebo-controlled, single-site clinical trial of semaglutide in adult (age 18 or older, n=100), obesity-related (BMI≥30), symptomatic asthma without type II diabetes. This study will monitor ...
https://clinicaltrials.gov/ct2/show/NCT03993132
Jun 22nd, 2022 - The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists ...
https://clinicaltrials.gov/ct2/show/NCT04461015
Jun 21st, 2022 - Study A (Insulin 0.4mU/Kg/min): Subjects will be admitted to the CRTU at approximately 1700 on the day prior to study. They will then consume a standard 10kcal/kg meal (55% carbohydrate, 30% fat, 15% protein, caffeine free) and fast overnight. Blo...
News 584 results
https://www.medscape.com/viewarticle/976139
Jun 24th, 2022 - Dasiglucagon, a glucagon analog approved for treating severe hypoglycemia, also appeared to be effective and highly acceptable for patients with type 1 diabetes with nonsevere hypoglycemia in a controlled, crossover study of 24 patients. In the he...
https://www.medscape.com/viewarticle/975212
Jun 23rd, 2022 - This transcript has been edited for clarity. In the 2022 Management of Hyperglycemia consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the focus has shifted. Regarding t...
https://www.mdedge.com/type-2-diabetes-icymi/article/255611/diabetes/t2d-meta-analysis-suggests-superiority-tirzepatide
Jun 22nd, 2022 - Key clinical point : In patients with type 2 diabetes (T2D), once-weekly tirzepatide demonstrated dose-dependent superiority on glycemic efficacy vs. placebo, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), and basal insulin, with.
https://www.medscape.com/viewarticle/976020
Jun 22nd, 2022 - Dr Viktor R. Curovic A one-size-fits-all approach may not be the best way to treat albuminuria in patients with diabetes. Multiple guidelines recommend a renin-angiotensin system (RAS) inhibitor (an angiotensin-converting enzyme inhibitor or angio...
https://www.medscape.com/viewarticle/975096
Jun 20th, 2022 - This transcript has been edited for clarity. My career has really been around clinical research in obesity and diabetes. I was part of the Diabetes Prevention Program, the Look AHEAD study, and the POUNDS LOST study. I helped develop the DASH diet...
